Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies
Published date:
06/08/2022
Excerpt:
Patients preserved FAT1 or LRP1B variants but without TP53 variants had worse progression free survival for receiving lenvatinib combined with immune checkpoint inhibitors after recurrence (HR = 17.1, p < 0.001).